ABM Therapeutics Completes $30 Million Series B Financing

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2022-01-05

Source: Viva Biotech

[Abstract]:The funds will be used to accelerate the clinical research of ABM-1310 in China and the U.S., develop several existing preclinical projects, and build the company's pipeline and the management team.

Shanghai and San Diego—January 4th, 2022, ABM Therapeutics, invested and incubated by Viva BioInnovator, a biopharmaceutical company that focuses on small molecule research and development of novel drugs for the treatment of brain cancers, announced the completion of a $30M Series B financing. Photon Fund and HighLight Capital led the round. Other investors who joined the round include LongDAC, Delta Capital, Hermed Capital, Baidu and Sincere VC.

The funds will be used to accelerate the clinical research of ABM-1310 in China and the U.S., develop several existing preclinical projects, and build the company's pipeline and the management team. The innovative brain medicine R&D platform will be continuously optimized to maintain its edge in this new and increasingly competitive field.

Previous Page：Portfolio Highlights: Clinical and Financing Updates of QureBio, HAYA and Xlement Next Page：AlxplorerBio and AliveX, BIOCAST Reached a Strategic Collaboration Agreement, To Jointly Promote the Development of Precision Medicines of IBD

Back

Media contact: vivapr@vivabiotech.com